Why is Vaxcyte stock sliding in after-hours trading today?
Vaxcyte Inc. shares fell 5.8% in after-hours trading to $69.57 after announcing a $1 billion capital raise, including $500 million in common stock and $500 million in convertible notes. The decline followed a 52-week high of $90.75 after positive Phase 3 trial results for its pneumococcal vaccine candidate VAX-31, which met all co-primary endpoints. Analysts praised the results, with Jefferies and BTIG reiterating Buy ratings and an $89 price target.
How this was made
The 30-second read
Why it matters
The capital raise introduces significant dilution risk, which outweighed the trial news in after‑hours trading.
Market read
The announcement combines a material capital raise with breakthrough trial data, driving immediate price action and setting the short‑term outlook for Vaxcyte.
What to watch
Potential strategic partnerships or future pricing power in the pneumococcal market may offset dilution impact.
Background
Vaxcyte's VAX‑31 vaccine met all immunogenicity endpoints in its pivotal Phase 3 OPUS‑1 trial, a rare positive outcome for a late‑stage biotech.
Market effects
Biotech sector may see heightened scrutiny on dilution‑driven financing after positive data releases.
US biotech investors likely to adjust exposure to Vaxcyte and similar late‑stage vaccine developers.
Limited to US‑listed biotech; no broader macro impact.
Counterpoint
The trial success could drive a rebound once dilution concerns fade, presenting a buying opportunity.
Key entities
- companyVaxcyte Inc.
US‑listed biotech developing the VAX‑31 pneumococcal vaccine.
- analystJefferies
Provided a positive commentary on the trial results.
- analystBTIG
Reiterated a Buy rating with an $89 price target.
